Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.

Saved in:
Bibliographic Details
Title: Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
Authors: Hamilton MP; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA., Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, 94305, USA.
Source: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Oct; Vol. 30 (10), pp. 936-938.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-6367
DOI:10.1016/j.jtct.2024.09.002